Clinigen buys U.S. rights to Novartis’ cancer drug Proleukin

(Reuters) – British pharmaceutical firm Clinigen Group Plc said on Wednesday it acquired the U.S. rights to Swiss drugmaker Novartis AG’s skin and lung cancer drug Proleukin for a total of $210 million, including some future payments.

Clinigen, which now has global rights to the drug, expects the deal to add to its profitability this year, and forecast a growth in adjusted EBITDA for the six months ended December.